ESMA will consider the responses it receives to this consultation paper by 19 November 2021 and expects to publish a final report by the end of Q1 2022.
The European Securities and Markets Authority (ESMA), the EU’s securities markets regulator, today launches a consultation paper (CP) on the review of the Short Selling Regulation (SSR).
The CP sets out suggestions for operational improvements and policy clarifications on:
- the calculation of net short positions, the prohibition of uncovered
short selling and the locate rule under which short selling trades can
take place;
- the mechanism for transparency of net short positions and the
proposal to publish aggregated net short positions per issuer based on
all individual positions and the scope of the exemptions for shares that
are more heavily traded in a third country; and
- the introduction of a centralised notification and publication
system to reduce reporting burdens, increase cost efficiency and foster
ESMA’s monitoring capacity and coordination powers in case of potential
threats at EU level.
The CP also contains an empirical analysis of the impact of the short
selling bans adopted after the COVID-19 outbreak, with reference to the
effect of the bans on liquidity and volatility, concluding that current
intervention powers remain a useful tool in case of developments
impacting the resiliency of financial markets.
Next steps
ESMA will consider the responses it receives to this consultation paper by 19 November 2021
and expects to publish a final report by the end of Q1 2022. This CP
will primarily be of interest to issuers of financial instruments
admitted to trading or traded on a trading venue, investment firms,
market makers, primary dealers, persons who engage in short sales or
transactions resulting in net short positions.
esma70-156-3914_consultation_paper_on_the_review_of_certain_aspects_of_the_short_selling_regulation.pdf
ESMA
© ESMA
Key
Hover over the blue highlighted
text to view the acronym meaning
Hover
over these icons for more information
Comments:
No Comments for this Article